Hoosier Hcrn Gu17-295- A Phase II Trial Of Atezolizumab Plus Chemotherapy After Progression On Pd-1 Or Pd-L1 Inhibitor In Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma
Posted Date: Jul 8, 2020
- Investigator: Shuchi Gulati
- Specialties: Cancer, Oncology
- Type of Study: Drug
The primary goal of this study is to Evaluate PFS among patients to be treated with atezolizumab in combination with carboplatin + gemcitabine or docetaxel, who have cisplatin-ineligible metastatic urothelial carcinoma and who have progressed on prior PD-1 or PD-L1 inhibitor.
Criteria:
To Be Eligible: Must Have Diagnosis Of Unresectable Locally Advanced Urothelial Carcinoma, Ecog 0-2, No Progressive Metastatic Disease After Previous Treatment With Pd-1 Or Pd-L1 Inhibitor, No Ae/Complication From Pd-1 Or Pd-L1 Inhibitor Requiring Permanent Discontinuation, No Other Malignancy Within 4 Years, No Active Or Recent Uncontrolled Infection Or Disorder That May Impact Treatment
Keywords:
Urothelial Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com